The majority of intracranial expansive lesions are tumors. However, a wide range of lesions can mimic neoplastic pathology. Differentiating pseudotumoral lesions from brain tumors is crucial to patient management. This article describes the most common intracranial pseudotumors, with a focus on the imaging features that serve as clues to detect pseudotumors.

To assess the clinical usefulness of facet joint cryoneurolysis in patients suffering from back pain of facet origin. Twenty nine patients suffering from chronic low back pain > 3 months were consecutively included in this single centre between 2015 and 2018 and 45 cryoneurolysis were performed. The decision to perform cryoneurolysis was made by the operator and based on multiple criteria : clinical history of pain in favour of facet joint pain, imaging data and a positive response to at least one medial block test. The following criteria were noted prior to the procedure : pain location, mean duration of pain prior to denervation, laterality of the pain, and intensity (visual analogic scale (VAS) score 1–10). All cryoneurolysis were performed ambulatory under local anaesthesia and computed tomography (CT) guidance. Sensory and motor stimulation were performed at each treated level and correlated to pain outcome. Follow-up clinical examination was performed at 1, 3, 6 and 12 months after procedure and clinical effectiveness was defined as a 50 % pain decrease on VAS scores. A total of 29 patients with a mean age of 60, y.o were included in our study, including 11 men and 18 women. Prior to the procedure, mean VAS score was 7,31/10. A total of 45 procedures were performed and an average of 2 cycles were performed per localisation and per intervention. Thirty out of the 45 procedures performed were considered a success, that is, a global success rate of 66 % percent with a mean pain relief period of 6,8 months. There was no statistical difference in efficacy depending on the sensory stimulation threshold, no correlation was found between threshold evolution during the procedure and procedure success. Cryoneurolysis of the medial branch is effective in patient presenting with facet joint pain in 66 % of cases. It should be considered as an alternate tool to alleviate facet joint mediated pain, in accurately selected patients.

Purpose: The goal of this retrospective study was to investigate the differential diagnosis of endolymphatic hydrops in patients with Meniere's disease (MD) symptoms by using magnetic resonance imaging (MRI) with intravenous injection of gadolinium chelate and delayed acquisition. Material and method: Two hundred patients (133 women, 67 men; mean age = 67.2 +/- 11 ([SD] years) with unilateral MD underwent MRI at 3-T, between 4.5 and 5.5 hours after intravenous administration of gadoterate meglumine at a dose of 0.1 mmol/kg. MR images were analyzed for the presence of saccular hydrops, perilymphatic fistulae, inner ear malformations, semicircular canal (SCC) abnormal enhancement and brain lesions. We also tested the potential relationship between past history of gentamicin intratympanic administration and perilymphatic fistula presence and SCC aspect. Results: Saccular hydrops were found in 96/200 patients with MD (48%). Three patients (1.5%) had perilymphatic fistulas associated with saccular hydrops, as confirmed by surgery. There was a correlation between the presence of perilymphatic fistula and past history of intratympanic gentamicin administration (P = 0.02). We detected inner ear malformations in 5 patients (2.5%), SCC local enhancement in 15 patients (7.5%) always on the same side than the clinical symptoms of MD. There was a correlation between the presence of SCC abnormal enhancement and past intratympanic gentamicin administration (P = 0.001). Five patients (2.5%) had brain lesions along central cochleovestibular pathways. Conclusion: MRI may reveal brain lesions, SCC abnormalities and perilymphatic fistulae inpatients with clinical MD. (C) 2017 Editions francaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

BREV (Batterie Rapide d'Evaluation des fonctions cognitives) is a new evaluation test for the screening of cognitive disorders in 4-9-year-old children, based on a neuropsychological process. It is made up of 17 subtests which have been carefully standardized. It is not an intelligence test but a tool for children' health professionals to use as a rapid neuropsychological screening test. It is particularly recommended for any child with a school learning disorder or neurological history with a high risk of cognitive disturbances such as epilepsy. It may also be used as a systematic screening test.

BREV (Batterie Rapide d'Evaluation des fonctions cognitives) is a new evaluation test for the screening of cognitive disorders in 4-9-year-old children, based on a neuropsychological process. It is made up of 17 subtests which have been carefully standardized. It is not an intelligence test but a tool for children' health professionals to use as a rapid neuropsychological screening test. It is particularly recommended for any child with a school learning disorder or neurological history with a high risk of cognitive disturbances such as epilepsy. It may also be used as a systematic screening test. (C) 2001 Editions scientifiques et medicales Elsevier SAS.

BREV (Batterie Rapide d'Evaluation des fonctions cognitives) is a new evaluation test for the screening of cognitive disorders in 4-9-year-old children, based on a neuropsychological process. It is made up of 17 subtests which have been carefully standardized. It is not an intelligence test but a tool for children' health professionals to use as a rapid neuropsychological screening test. It is particularly recommended for any child with a school learning disorder or neurological history with a high risk of cognitive disturbances such as epilepsy. It may also be used as a systematic screening test.